Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Vicebio

Request full access

Multi-pathogen respiratory vaccines using Molecular Clamp technology

London, United KingdomFounded 2019Biotech & Life Sciences

About Vicebio

Vicebio is a London-based clinical-stage biotechnology company developing next-generation vaccines against respiratory viral infections. Established in 2019, the company focuses on multivalent vaccines designed to protect against several respiratory pathogens with a single shot, with a particular emphasis on older adults and immunocompromised people, who carry much of the burden of severe respiratory disease.

Its work is built on the Molecular Clamp technology, developed at The University of Queensland by Professors Paul Young, Daniel Watterson and Keith Chappell and licensed exclusively from UniQuest, the university's commercialisation arm. The Molecular Clamp is a protein tag that locks viral surface proteins in their prefusion conformation, the shape they hold before infecting a cell. Stabilising proteins in this state is intended to trigger a strong protective immune response while simplifying manufacturing, making it possible to produce fully liquid, ready-to-use vaccines that can be stored at standard refrigerated temperatures.

The lead candidate, VXB-241, is a bivalent vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and has entered Phase 1 clinical testing. The pipeline also includes VXB-251, a preclinical trivalent candidate targeting RSV, hMPV and parainfluenza virus type 3. Because the platform is not based on mRNA, it offers an alternative modality, and the company sees potential applications across other viral families such as influenza and coronaviruses.

Vicebio is led by Emmanuel Hanon, a vaccine development specialist formerly at GSK Vaccines, with co-inventor Keith Chappell serving as Principal Scientist. The company now operates as part of Sanofi.

Source: Dealroom company data

Vicebio in the London ecosystem

Live from Dealroom

The Vicebio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

Series B and later7 investors entered at this stage

Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Vicebio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.